Literature DB >> 31515809

Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis.

Eunhye G Kang1, Poornima Krishnamurthy Narayana2, Isabelle J Pouliquen3, Monica C Lopez4, M Celeste Ferreira-Cornwell1, John A Getsy1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31515809     DOI： 10.1111/all.14050

Source DB:  PubMed          Journal:  Allergy        ISSN： 0105-4538            Impact factor:   13.146


× No keyword cloud information.
  10 in total

Review 1.  From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.

Authors:  Ian D Pavord; Elisabeth H Bel; Arnaud Bourdin; Robert Chan; Joseph K Han; Oliver N Keene; Mark C Liu; Neil Martin; Alberto Papi; Florence Roufosse; Jonathan Steinfeld; Michael E Wechsler; Steven W Yancey
Journal:  Allergy       Date:  2021-09-16       Impact factor: 14.710

Review 2.  Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis.

Authors:  El-Bdaoui Haddad; Sonya L Cyr; Kazuhiko Arima; Robert A McDonald; Noah A Levit; Frank O Nestle
Journal:  Dermatol Ther (Heidelb)       Date:  2022-05-21

Review 3.  Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Authors:  Jinsha Liu; Joey Paolo Ting; Shams Al-Azzam; Yun Ding; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

4.  Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies.

Authors:  Elizabeth A Jacobsen; David J Jackson; Enrico Heffler; Sameer K Mathur; Albert J Bredenoord; Ian D Pavord; Praveen Akuthota; Florence Roufosse; Marc E Rothenberg
Journal:  Annu Rev Immunol       Date:  2021-03-01       Impact factor: 28.527

Review 5.  What does elevated TARC/CCL17 expression tell us about eosinophilic disorders?

Authors:  Julien Catherine; Florence Roufosse
Journal:  Semin Immunopathol       Date:  2021-05-19       Impact factor: 9.623

Review 6.  Lessons learned from targeting eosinophils in human disease.

Authors:  Fei Li Kuang; Bruce S Bochner
Journal:  Semin Immunopathol       Date:  2021-04-23       Impact factor: 11.759

Review 7.  Therapeutic New Era for Atopic Dermatitis: Part 1. Biologics.

Authors:  Jiyoung Ahn; Yusung Choi; Eric Lawrence Simpson
Journal:  Ann Dermatol       Date:  2020-12-30       Impact factor: 1.444

8.  Low-dose intralesional injection of 5-fluorouracil and triamcinolone reduces tissue resident memory T cells in chronic eczema.

Authors:  Yun Wu; Guo-Jiang Wang; Hui-Qiong He; Hai-Hong Qin; Wen-Tong Shen; Yue Yu; Xun Zhang; Mao-Lin Zhou; Jian-Biao Fei
Journal:  World J Clin Cases       Date:  2022-01-07       Impact factor: 1.337

Review 9.  Eosinophils in skin diseases.

Authors:  Susanne Radonjic-Hoesli; Marie-Charlotte Brüggen; Laurence Feldmeyer; Hans-Uwe Simon; Dagmar Simon
Journal:  Semin Immunopathol       Date:  2021-06-07       Impact factor: 9.623

Review 10.  Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas.

Authors:  Karol Kołkowski; Magdalena Trzeciak; Małgorzata Sokołowska-Wojdyło
Journal:  Int J Mol Sci       Date:  2021-12-13       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.